Literature DB >> 10187776

The role of phosphatidylinositol 3-kinase in vascular endothelial growth factor signaling.

G D Thakker1, D P Hajjar, W A Muller, T K Rosengart.   

Abstract

Vascular endothelial growth factor (VEGF) receptor Flk-1/KDR in endothelial cells is activated during vasculogenesis and angiogenesis upon ligand-receptor interaction. Activated Flk-1/KDR has been shown to recruit Src homology 2 domain-containing signaling molecules that are known to serve as links to the activation of the mitogen-activated protein (MAP) kinase signaling pathway. To define the functional significance of phosphatidylinositol (PI) 3-kinase in VEGF signaling, we have examined its role in human umbilical vein endothelial cell (HUVEC) cycle progression. We show herein that p85, the regulatory subunit of PI 3-kinase, is constitutively associated with Flk-1/KDR. The treatment of HUVECs with VEGF promoted tyrosine autophosphorylation of Flk-1/KDR and also induced phosphorylation of p85. This was followed by an increase in the PI 3-kinase activity, which was sensitive to wortmannin, a potent PI 3-kinase inhibitor. VEGF also induced a striking activation of MAP kinase in a time-dependent manner. Inhibition studies with both a dominant-negative p85 mutant and the PI 3-kinase inhibitor, wortmannin, were employed to show for the first time that VEGF-stimulated PI 3-kinase modulates MAP kinase activation and nuclear events such as transcription from c-fos promoter and entry into the synthesis (S)-phase. Our data demonstrate the importance of PI 3-kinase as a necessary signaling component of VEGF-mediated cell cycle progression.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10187776     DOI: 10.1074/jbc.274.15.10002

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  45 in total

Review 1.  Angiogenesis.

Authors:  C D Kontos; B H Annex
Journal:  Curr Atheroscler Rep       Date:  1999-09       Impact factor: 5.113

2.  Vascular endothelial growth factor and the in vivo increase in plasma extravasation in the hamster cheek pouch.

Authors:  M Félétou; J Staczek; J Duhault
Journal:  Br J Pharmacol       Date:  2001-03       Impact factor: 8.739

3.  Differential mitogenic responses of human macrovascular and microvascular endothelial cells to cytokines underline their phenotypic heterogeneity.

Authors:  I Lang; C Hoffmann; H Olip; M A Pabst; T Hahn; G Dohr; G Desoye
Journal:  Cell Prolif       Date:  2001-06       Impact factor: 6.831

4.  Targeting angiogenesis: structural characterization and biological properties of a de novo engineered VEGF mimicking peptide.

Authors:  Luca Domenico D'Andrea; Guido Iaccarino; Roberto Fattorusso; Daniela Sorriento; Concetta Carannante; Domenica Capasso; Bruno Trimarco; Carlo Pedone
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-26       Impact factor: 11.205

Review 5.  VEGFR-1 and VEGFR-2: two non-identical twins with a unique physiognomy.

Authors:  Nader Rahimi
Journal:  Front Biosci       Date:  2006-01-01

6.  Kinase domain insert containing receptor promotor controlled suicide gene system kills human umbilical vein endothelial cells.

Authors:  Zong-Hai Huang; Wen-Yu Yang; Qi Cheng; Jing-Long Yu; Zhou Li; Zong-Yan Tong; Hui-Juan Song; Xiao-Yan Che
Journal:  World J Gastroenterol       Date:  2005-06-28       Impact factor: 5.742

7.  Selective induction of neuropilin-1 by vascular endothelial growth factor (VEGF): a mechanism contributing to VEGF-induced angiogenesis.

Authors:  Hideyasu Oh; Hitoshi Takagi; Atsushi Otani; Shinji Koyama; Seiji Kemmochi; Akiyoshi Uemura; Yoshihito Honda
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-26       Impact factor: 11.205

8.  Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis.

Authors:  Zhao-Jun Liu; Takashi Shirakawa; Yan Li; Akinobu Soma; Masahiro Oka; G Paolo Dotto; Ronald M Fairman; Omaida C Velazquez; Meenhard Herlyn
Journal:  Mol Cell Biol       Date:  2003-01       Impact factor: 4.272

9.  Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006).

Authors:  Danielle A Murphy; Sosina Makonnen; Wiem Lassoued; Michael D Feldman; Christopher Carter; William M F Lee
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

10.  Cooperative effect of roscovitine and irradiation targets angiogenesis and induces vascular destabilization in human breast carcinoma.

Authors:  L Maggiorella; C Aubel; C Haton; F Milliat; E Connault; P Opolon; E Deutsch; J Bourhis
Journal:  Cell Prolif       Date:  2009-02       Impact factor: 6.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.